Clinical Trial Update: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) [Phase 1]

View source ↗

Summary

A Phase 1 trial update evaluating the AKT inhibitor ipatasertib in combination with endocrine therapy and a CDK4/6 inhibitor for metastatic breast cancer (TAKTI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ipatasertib (ipatasertib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING